首页 > 最新文献

Clinical & Translational Oncology最新文献

英文 中文
Value of circulating tumor cell assisting low-dose computed tomography in screening pulmonary nodules based on existing liquid biopsy techniques: a systematic review with meta-analysis and trial sequential analysis. 基于现有液体活检技术的循环肿瘤细胞辅助低剂量计算机断层扫描在筛查肺结节中的价值:荟萃分析和试验序列分析的系统综述。
IF 2.8 3区 医学 Q2 ONCOLOGY Pub Date : 2024-12-01 Epub Date: 2024-06-13 DOI: 10.1007/s12094-024-03556-8
Yixian Wang, Yuqing Duan, Dingjie Guo, Hongbo Lv, Qiong Li, Xuan Liu, Na Qiao, Hengyu Meng, Xin Zhang, Linwei Lan, Xiumin Liu, Xin Liu

Objective: This study aims to assess the diagnostic utility of circulating tumor cells (CTCs) in conjunction with low-dose computed tomography (LDCT) for differentiating between benign and malignant pulmonary nodules and to substantiate the foundation for their integration into clinical practice.

Methods: A systematic literature review was performed independently by two researchers utilizing databases including PubMed, Web of Science, The Cochrane Library, Embase, and Medline, to collate studies up to September 15, 2023, that investigated the application of CTCs in diagnosing pulmonary nodules. A meta-analysis was executed employing Stata 15.0 and Revman 5.4 to calculate the pooled sensitivity, specificity, positive and negative likelihood ratios (PLR and NLR), diagnostic odds ratio (DOR), and the area under the receiver operating characteristic curve (AUC). Additionally, trial sequential analysis was conducted using dedicated TSA software.

Results: The selection criteria identified 16 studies, encompassing a total of 3409 patients. The meta-analysis revealed that CTCs achieved a pooled sensitivity of 0.84 (95% CI 0.80 to 0.87), specificity of 0.80 (95% CI 0.73 to 0.86), PLR of 4.23 (95% CI 3.12 to 5.72), NLR of 0.20 (95% CI 0.16 to 0.25), DOR of 20.92 (95% CI 13.52 to 32.36), and AUC of 0.89 (95% CI 0.86 to 0.93).

Conclusions: Circulating tumor cells demonstrate substantial diagnostic accuracy in distinguishing benign from malignant pulmonary nodules. The incorporation of CTCs into the diagnostic protocol can significantly augment the diagnostic efficacy of LDCT in screening for malignant lung diseases.

研究目的本研究旨在评估循环肿瘤细胞(CTCs)结合低剂量计算机断层扫描(LDCT)在区分肺部结节良性和恶性方面的诊断效用,并为将其纳入临床实践奠定基础:两位研究人员利用 PubMed、Web of Science、The Cochrane Library、Embase 和 Medline 等数据库独立进行了系统性文献综述,整理了截至 2023 年 9 月 15 日有关 CTCs 在诊断肺结节中应用的研究。利用 Stata 15.0 和 Revman 5.4 进行了荟萃分析,以计算汇总的灵敏度、特异性、阳性和阴性似然比(PLR 和 NLR)、诊断几率比(DOR)以及接收者操作特征曲线下面积(AUC)。此外,还使用专用的 TSA 软件进行了试验序列分析:筛选标准确定了 16 项研究,共涉及 3409 名患者。荟萃分析表明,CTCs的集合敏感性为0.84(95% CI 0.80至0.87),特异性为0.80(95% CI 0.73至0.86),PLR为4.23(95% CI 3.12至5.72),NLR为0.20(95% CI 0.16至0.25),DOR为20.92(95% CI 13.52至32.36),AUC为0.89(95% CI 0.86至0.93):循环肿瘤细胞在区分肺结节良恶性方面具有很高的诊断准确性。结论:循环肿瘤细胞在区分良性和恶性肺结节方面具有很高的诊断准确性,将循环肿瘤细胞纳入诊断方案可显著提高 LDCT 在筛查恶性肺部疾病方面的诊断效果。
{"title":"Value of circulating tumor cell assisting low-dose computed tomography in screening pulmonary nodules based on existing liquid biopsy techniques: a systematic review with meta-analysis and trial sequential analysis.","authors":"Yixian Wang, Yuqing Duan, Dingjie Guo, Hongbo Lv, Qiong Li, Xuan Liu, Na Qiao, Hengyu Meng, Xin Zhang, Linwei Lan, Xiumin Liu, Xin Liu","doi":"10.1007/s12094-024-03556-8","DOIUrl":"10.1007/s12094-024-03556-8","url":null,"abstract":"<p><strong>Objective: </strong>This study aims to assess the diagnostic utility of circulating tumor cells (CTCs) in conjunction with low-dose computed tomography (LDCT) for differentiating between benign and malignant pulmonary nodules and to substantiate the foundation for their integration into clinical practice.</p><p><strong>Methods: </strong>A systematic literature review was performed independently by two researchers utilizing databases including PubMed, Web of Science, The Cochrane Library, Embase, and Medline, to collate studies up to September 15, 2023, that investigated the application of CTCs in diagnosing pulmonary nodules. A meta-analysis was executed employing Stata 15.0 and Revman 5.4 to calculate the pooled sensitivity, specificity, positive and negative likelihood ratios (PLR and NLR), diagnostic odds ratio (DOR), and the area under the receiver operating characteristic curve (AUC). Additionally, trial sequential analysis was conducted using dedicated TSA software.</p><p><strong>Results: </strong>The selection criteria identified 16 studies, encompassing a total of 3409 patients. The meta-analysis revealed that CTCs achieved a pooled sensitivity of 0.84 (95% CI 0.80 to 0.87), specificity of 0.80 (95% CI 0.73 to 0.86), PLR of 4.23 (95% CI 3.12 to 5.72), NLR of 0.20 (95% CI 0.16 to 0.25), DOR of 20.92 (95% CI 13.52 to 32.36), and AUC of 0.89 (95% CI 0.86 to 0.93).</p><p><strong>Conclusions: </strong>Circulating tumor cells demonstrate substantial diagnostic accuracy in distinguishing benign from malignant pulmonary nodules. The incorporation of CTCs into the diagnostic protocol can significantly augment the diagnostic efficacy of LDCT in screening for malignant lung diseases.</p>","PeriodicalId":50685,"journal":{"name":"Clinical & Translational Oncology","volume":" ","pages":"3252-3263"},"PeriodicalIF":2.8,"publicationDate":"2024-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141312243","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Clinical characteristics and prognostic analysis of metachronous bilateral breast carcinoma: a retrospective study based on propensity score matching. 近端双侧乳腺癌的临床特征和预后分析:基于倾向评分匹配的回顾性研究。
IF 2.8 3区 医学 Q2 ONCOLOGY Pub Date : 2024-12-01 Epub Date: 2024-05-27 DOI: 10.1007/s12094-024-03528-y
Xinle Wang, Xinrui Wang, Lijing Cai, Cong Zhang, Yuntao Li
<p><strong>Background: </strong>To investigate clinical characteristics, treatment, outcomes, and prognostic risk factors of metachronous bilateral breast carcinoma (MBBC) and provide a theoretical basis for clinical management of MBBC.</p><p><strong>Methods: </strong>This was a retrospective study. From January 1, 2010 to March 31, 2022, a total of 23,010 patients with breast cancer underwent surgical treatment at the Breast Center of the Fourth Hospital of Hebei Medical University, including 386 patients with MBBC. Propensity score matching (PSM) was performed on MBBC patients and unilateral breast cancer (UBC) patients in a 1:1 ratio, and 210 UBC patients and 210 MBBC patients were finally matched. Clinical medical records of all patients were collected, including age of onset, family history of breast cancer, tumor size, lymph node status, TNM stage, mode of surgery, menstruation, pathological type, immunohistochemical (IHC) typing, treatment, disease-free survival (DFS), and overall survival (OS).</p><p><strong>Results: </strong>The result showed that age of onset of the second primary cancer (SPC) was significantly older than that of the first primary cancer (FPC) (P = 0.024). Baseline data from MPPC patients showed that the tumor size of FPC was significantly larger than that of SPC (P = 0.043), and the proportion of PR ( +) in FPC is significantly higher than that in SPC (P = 0.045). Among MBBC patients with FPC for estrogen receptor (ER) or progesterone receptor (PR) ( +) and Her-2 (-), clinical characteristics and treatment results showed that the proportion of PR ( +) in the drug-resistant group was significantly lower than that in the non-drug-resistant group. The 2-year OS rate of SPC in the drug-resistant group was significantly shorter than those of the non-drug-resistant group (78.9% vs 100%, P < 0.05). The result of PSM-based comparison between MBBC patients and UBC patients showed significantly lower proportion of MBBC patients with SPC received chemotherapy compared to UBC patients (P = 0.026), and there was no significant difference in OS and DFS between SPC course of MBBC patients and UBC patients (P > 0.05). The univariate analysis showed that high TNM stage was a risk factor for death and disease progression in MBBC patients, with the risk of death in stage III MBBC patients being about 5 times higher than that in stage I MBBC patients (HR = 4.97, 95%CI = 1.42-17.31, P = 0.012), and the risk of disease recurrence being about 3.5 times higher than that in stage I MBBC patients (HR = 3.55, 95%CI = 1.07-11.81, P = 0.039).</p><p><strong>Conclusion: </strong>In summary, this study presented clinical characteristics, treatment options, and outcomes of MBBC patients and patients with MBBC who were resistant to endocrine therapy have a worse SPC survival prognosis. The course of SPC in MBBC patients was similar to that of UBC in terms of prognosis and survival, which suggested that SPC can be treated according to UBC treatment regi
背景:研究双侧乳腺癌(MBBC)的临床特征、治疗、预后和风险因素,为临床治疗提供理论依据:目的:研究隐匿性双侧乳腺癌(MBBC)的临床特征、治疗、结果和预后风险因素,为MBBC的临床治疗提供理论依据:这是一项回顾性研究。2010年1月1日至2022年3月31日,共有23010名乳腺癌患者在河北医科大学第四医院乳腺中心接受了手术治疗,其中包括386名MBBC患者。对MBBC患者和单侧乳腺癌(UBC)患者按1:1的比例进行倾向评分匹配(PSM),最终匹配出210名UBC患者和210名MBBC患者。收集了所有患者的临床病历,包括发病年龄、乳腺癌家族史、肿瘤大小、淋巴结状态、TNM分期、手术方式、月经、病理类型、免疫组化(IHC)分型、治疗情况、无病生存期(DFS)和总生存期(OS):结果显示,第二原发癌(SPC)的发病年龄明显大于第一原发癌(FPC)(P = 0.024)。MPPC患者的基线数据显示,FPC的肿瘤大小明显大于SPC(P = 0.043),FPC中PR(+)的比例明显高于SPC(P = 0.045)。在雌激素受体(ER)或孕激素受体(PR)(+)和Her-2(-)的FPC MBBC患者中,临床特征和治疗结果显示,耐药组中PR(+)的比例明显低于非耐药组。耐药组 SPC 的 2 年 OS 率明显短于非耐药组(78.9% vs 100%,P 0.05)。单变量分析显示,TNM分期高是MBBC患者死亡和疾病进展的危险因素,III期MBBC患者死亡风险约为I期MBBC患者的5倍(HR=4.97,95%CI=1.42-17.31,P=0.012),疾病复发风险约为I期MBBC患者的3.5倍(HR=3.55,95%CI=1.07-11.81,P=0.039):总之,本研究介绍了MBBC患者的临床特征、治疗方案和预后,对内分泌治疗耐药的MBBC患者SPC生存预后较差。在预后和生存率方面,MBBC 患者的 SPC 病程与 UBC 相似,这表明 SPC 可按照 UBC 的治疗方案进行治疗。TNM分期高是SPC患者预后的危险因素。
{"title":"Clinical characteristics and prognostic analysis of metachronous bilateral breast carcinoma: a retrospective study based on propensity score matching.","authors":"Xinle Wang, Xinrui Wang, Lijing Cai, Cong Zhang, Yuntao Li","doi":"10.1007/s12094-024-03528-y","DOIUrl":"10.1007/s12094-024-03528-y","url":null,"abstract":"&lt;p&gt;&lt;strong&gt;Background: &lt;/strong&gt;To investigate clinical characteristics, treatment, outcomes, and prognostic risk factors of metachronous bilateral breast carcinoma (MBBC) and provide a theoretical basis for clinical management of MBBC.&lt;/p&gt;&lt;p&gt;&lt;strong&gt;Methods: &lt;/strong&gt;This was a retrospective study. From January 1, 2010 to March 31, 2022, a total of 23,010 patients with breast cancer underwent surgical treatment at the Breast Center of the Fourth Hospital of Hebei Medical University, including 386 patients with MBBC. Propensity score matching (PSM) was performed on MBBC patients and unilateral breast cancer (UBC) patients in a 1:1 ratio, and 210 UBC patients and 210 MBBC patients were finally matched. Clinical medical records of all patients were collected, including age of onset, family history of breast cancer, tumor size, lymph node status, TNM stage, mode of surgery, menstruation, pathological type, immunohistochemical (IHC) typing, treatment, disease-free survival (DFS), and overall survival (OS).&lt;/p&gt;&lt;p&gt;&lt;strong&gt;Results: &lt;/strong&gt;The result showed that age of onset of the second primary cancer (SPC) was significantly older than that of the first primary cancer (FPC) (P = 0.024). Baseline data from MPPC patients showed that the tumor size of FPC was significantly larger than that of SPC (P = 0.043), and the proportion of PR ( +) in FPC is significantly higher than that in SPC (P = 0.045). Among MBBC patients with FPC for estrogen receptor (ER) or progesterone receptor (PR) ( +) and Her-2 (-), clinical characteristics and treatment results showed that the proportion of PR ( +) in the drug-resistant group was significantly lower than that in the non-drug-resistant group. The 2-year OS rate of SPC in the drug-resistant group was significantly shorter than those of the non-drug-resistant group (78.9% vs 100%, P &lt; 0.05). The result of PSM-based comparison between MBBC patients and UBC patients showed significantly lower proportion of MBBC patients with SPC received chemotherapy compared to UBC patients (P = 0.026), and there was no significant difference in OS and DFS between SPC course of MBBC patients and UBC patients (P &gt; 0.05). The univariate analysis showed that high TNM stage was a risk factor for death and disease progression in MBBC patients, with the risk of death in stage III MBBC patients being about 5 times higher than that in stage I MBBC patients (HR = 4.97, 95%CI = 1.42-17.31, P = 0.012), and the risk of disease recurrence being about 3.5 times higher than that in stage I MBBC patients (HR = 3.55, 95%CI = 1.07-11.81, P = 0.039).&lt;/p&gt;&lt;p&gt;&lt;strong&gt;Conclusion: &lt;/strong&gt;In summary, this study presented clinical characteristics, treatment options, and outcomes of MBBC patients and patients with MBBC who were resistant to endocrine therapy have a worse SPC survival prognosis. The course of SPC in MBBC patients was similar to that of UBC in terms of prognosis and survival, which suggested that SPC can be treated according to UBC treatment regi","PeriodicalId":50685,"journal":{"name":"Clinical & Translational Oncology","volume":" ","pages":"3065-3074"},"PeriodicalIF":2.8,"publicationDate":"2024-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141154865","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Autophagy in cholangiocarcinoma: a comprehensive review about roles and regulatory mechanisms. 自噬在胆管癌中的作用和调控机制综述
IF 2.8 3区 医学 Q2 ONCOLOGY Pub Date : 2024-11-25 DOI: 10.1007/s12094-024-03797-7
Yuxia Yang, Qiuyan Li, Lok Ting Chu, Xiaocong Lin, Helian Chen, Linsong Chen, Jinjing Tang, Tao Zeng

The role of autophagy in cholangiocarcinogenesis and its development is intricate. Autophagy has a dual role in cholangiocarcinoma, and understanding the function and mechanism of autophagy in cholangiocarcinoma is pivotal in guiding therapeutic approaches to its treatment in clinical settings. Recent studies have revealed that autophagy is involved in the complex biological behavior of cholangiocarcinoma. In this review, we have summarized the genes and drugs that would promote or inhibit autophagy, leading to change in cellular behaviors of cholangiocarcinoma, including apoptosis, proliferation, invasion and migration, and influence its cellular drug resistance. In addition, we concluded the signaling pathways modulating autophagy in cholangiocarcinoma cells, including PI3K/AKT/mTOR,p38MAPK,AMPK/mTOR,LKB1-AMPK, and AKT/WNK1, and ERK signaling pathways, which subsequently impacting apoptosis, death, migration, invasion, and proliferation. In conclusion, we would like that we can provide ideas for future cholangiocarcinoma treatment by comprehensively summarizing the latest studies on the relationship between autophagy and cholangiocarcinoma, including the factors affecting autophagy and related signaling pathways.

自噬在胆管癌发生和发展中的作用错综复杂。自噬在胆管癌中具有双重作用,了解自噬在胆管癌中的功能和机制对于指导临床治疗方法至关重要。最近的研究发现,自噬参与了胆管癌复杂的生物学行为。在这篇综述中,我们总结了促进或抑制自噬的基因和药物,它们会导致胆管癌细胞行为的改变,包括凋亡、增殖、侵袭和迁移,并影响其细胞耐药性。此外,我们还总结了调节胆管癌细胞自噬的信号通路,包括 PI3K/AKT/mTOR、p38MAPK、AMPK/mTOR、LKB1-AMPK、AKT/WNK1 和 ERK 信号通路,这些信号通路随后会影响细胞的凋亡、死亡、迁移、侵袭和增殖。总之,我们希望通过全面总结自噬与胆管癌关系的最新研究,包括影响自噬的因素及相关信号通路,为未来胆管癌的治疗提供思路。
{"title":"Autophagy in cholangiocarcinoma: a comprehensive review about roles and regulatory mechanisms.","authors":"Yuxia Yang, Qiuyan Li, Lok Ting Chu, Xiaocong Lin, Helian Chen, Linsong Chen, Jinjing Tang, Tao Zeng","doi":"10.1007/s12094-024-03797-7","DOIUrl":"https://doi.org/10.1007/s12094-024-03797-7","url":null,"abstract":"<p><p>The role of autophagy in cholangiocarcinogenesis and its development is intricate. Autophagy has a dual role in cholangiocarcinoma, and understanding the function and mechanism of autophagy in cholangiocarcinoma is pivotal in guiding therapeutic approaches to its treatment in clinical settings. Recent studies have revealed that autophagy is involved in the complex biological behavior of cholangiocarcinoma. In this review, we have summarized the genes and drugs that would promote or inhibit autophagy, leading to change in cellular behaviors of cholangiocarcinoma, including apoptosis, proliferation, invasion and migration, and influence its cellular drug resistance. In addition, we concluded the signaling pathways modulating autophagy in cholangiocarcinoma cells, including PI3K/AKT/mTOR,p38MAPK,AMPK/mTOR,LKB1-AMPK, and AKT/WNK1, and ERK signaling pathways, which subsequently impacting apoptosis, death, migration, invasion, and proliferation. In conclusion, we would like that we can provide ideas for future cholangiocarcinoma treatment by comprehensively summarizing the latest studies on the relationship between autophagy and cholangiocarcinoma, including the factors affecting autophagy and related signaling pathways.</p>","PeriodicalId":50685,"journal":{"name":"Clinical & Translational Oncology","volume":" ","pages":""},"PeriodicalIF":2.8,"publicationDate":"2024-11-25","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142711645","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Exploring the efficacy and safety of laser interstitial thermal therapy for recurrent high-grade glioma: the first prospective cohort in China. 探索激光间质热疗治疗复发性高级别胶质瘤的疗效和安全性:中国首个前瞻性队列。
IF 2.8 3区 医学 Q2 ONCOLOGY Pub Date : 2024-11-23 DOI: 10.1007/s12094-024-03779-9
Yihe Wang, Sichang Chen, Jianwei Shi, Ting Tang, Yang Dai, Jinkun Xu, Penghu Wei, Xiaotong Fan, Jie Lu, Yongzhi Shan, Guoguang Zhao

Objective: Recurrent high-grade gliomas are complicated cancers that require additional treatment options. Magnetic resonance-guided laser interstitial thermal therapy (MRgLITT) is a safe method for treating recurrent high-grade glioma; however, its use in China has not been reported. In this study, we aimed to investigate the safety and efficacy of an MRgLITT system (SinoVision™) developed in China for treating recurrent high-grade glioma.

Methods: We included a prospective cohort of patients with recurrent high-grade glioma treated with the Chinese MRgLITT system between March 2021 and December 2022. Clinical data, including basic information, complication rates, outcomes, and survival analyses, were collected for patients who had at least 12 months of follow-up.

Results: 32 patients who completed a rountine follow-up period were enrolled. The estimated 1-year overall survival rate was 65.63%, including 56.52% and 88.89% patients with World Health Organization Grades IV and III gliomas, respectively. Baseline Karnofsky Performance Scale score, tumor grade and volume, and post-LITT chemo- and or radiotherapy were positive factors associated with MRgLITT for recurrent high-grade glioma outcomes. The overall complication rate was 9.38%.

Conclusion: The Chinese MRgLITT system is a safe and effective treatment option for recurrent high-grade glioma. As it is a minimally invasive treatment approach that can be tailored to the individual's anatomy and physiology, MRg LITT may offer a viable alternative for patients who are not suitable candidates for conventional surgical resection.

目的:复发性高级别胶质瘤是一种复杂的癌症,需要额外的治疗方案。磁共振引导下激光间质热疗(MRgLITT)是治疗复发性高级别胶质瘤的一种安全方法,但在中国的应用尚未见报道。在这项研究中,我们旨在调查中国开发的 MRgLITT 系统(SinoVision™)治疗复发性高级别胶质瘤的安全性和有效性:我们纳入了 2021 年 3 月至 2022 年 12 月间使用中国 MRgLITT 系统治疗的复发性高级别胶质瘤患者的前瞻性队列。我们收集了至少随访 12 个月的患者的临床数据,包括基本信息、并发症发生率、结果和生存分析:结果:32 名患者完成了为期一个月的随访。估计1年总生存率为65.63%,其中世界卫生组织IV级和III级胶质瘤患者的生存率分别为56.52%和88.89%。基线卡诺夫斯基表现量表评分、肿瘤级别和体积以及LITT后化疗和放疗是MRgLITT治疗复发性高级别胶质瘤疗效的积极相关因素。总并发症发生率为9.38%:中国的MRgLITT系统是复发性高级别胶质瘤的一种安全有效的治疗方案。结论:中国的MRgLITT系统是治疗复发性高级别胶质瘤的安全有效的方法。由于它是一种微创治疗方法,可根据个人的解剖和生理特点量身定制,MRgLITT可为不适合传统手术切除的患者提供一种可行的替代方案。
{"title":"Exploring the efficacy and safety of laser interstitial thermal therapy for recurrent high-grade glioma: the first prospective cohort in China.","authors":"Yihe Wang, Sichang Chen, Jianwei Shi, Ting Tang, Yang Dai, Jinkun Xu, Penghu Wei, Xiaotong Fan, Jie Lu, Yongzhi Shan, Guoguang Zhao","doi":"10.1007/s12094-024-03779-9","DOIUrl":"https://doi.org/10.1007/s12094-024-03779-9","url":null,"abstract":"<p><strong>Objective: </strong>Recurrent high-grade gliomas are complicated cancers that require additional treatment options. Magnetic resonance-guided laser interstitial thermal therapy (MRgLITT) is a safe method for treating recurrent high-grade glioma; however, its use in China has not been reported. In this study, we aimed to investigate the safety and efficacy of an MRgLITT system (SinoVision™) developed in China for treating recurrent high-grade glioma.</p><p><strong>Methods: </strong>We included a prospective cohort of patients with recurrent high-grade glioma treated with the Chinese MRgLITT system between March 2021 and December 2022. Clinical data, including basic information, complication rates, outcomes, and survival analyses, were collected for patients who had at least 12 months of follow-up.</p><p><strong>Results: </strong>32 patients who completed a rountine follow-up period were enrolled. The estimated 1-year overall survival rate was 65.63%, including 56.52% and 88.89% patients with World Health Organization Grades IV and III gliomas, respectively. Baseline Karnofsky Performance Scale score, tumor grade and volume, and post-LITT chemo- and or radiotherapy were positive factors associated with MRgLITT for recurrent high-grade glioma outcomes. The overall complication rate was 9.38%.</p><p><strong>Conclusion: </strong>The Chinese MRgLITT system is a safe and effective treatment option for recurrent high-grade glioma. As it is a minimally invasive treatment approach that can be tailored to the individual's anatomy and physiology, MRg LITT may offer a viable alternative for patients who are not suitable candidates for conventional surgical resection.</p>","PeriodicalId":50685,"journal":{"name":"Clinical & Translational Oncology","volume":" ","pages":""},"PeriodicalIF":2.8,"publicationDate":"2024-11-23","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142696023","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Comprehensing the role of serum GGT in colorectal carcinoma: cancer risk, prognostic and diagnostic significance. 全面了解血清 GGT 在结直肠癌中的作用:癌症风险、预后和诊断意义。
IF 2.8 3区 医学 Q2 ONCOLOGY Pub Date : 2024-11-20 DOI: 10.1007/s12094-024-03791-z
Sristi Anupam, Simran Goel, Dinesh Kumar Mehta, Rina Das

Effective biomarkers are necessary for early diagnosis, prognosis, and therapy monitoring of colorectal cancer (CRC), a disease that continues to be a major worldwide health problem. Due to a potential connection to colorectal cancer, serum gamma-glutamyl transferase (GGT), an important enzyme in metabolism of glutathione and cellular stress response, has drawn attention. GGT is an essential component of the antioxidant system that protects against oxidative stress. It is mostly found in organs such as the liver, kidneys, and biliary tract. Numerous health problems, such as metabolic disorders, liver illnesses, and several types of cancer, are linked to elevated blood GGT levels. This review aims to clarify the function of serum GGT in colorectal cancer by examining clinical research conducted over the past 20 years. A comprehensive analysis of pertinent literature identifies associations between high blood GGT levels and carcinoma of the colon risk, prognosis, and diagnostic potential. Increased GGT and a higher risk of colorectal cancer are positively correlated, according to epidemiological data consistently. The predictive capacity of GGT for colorectal adenomas underscores its use in early identification and preventive approaches. Additional clinical evidence indicates that higher GGT levels in CRC patients are associated with poorer outcomes, such as invasion of lymph nodes, advanced tumour stages, and decreased overall survival. Furthermore, changes in GGT levels after therapy offer information about patient survival and treatment effectiveness, highlighting its importance in therapy monitoring. In summary, this review underscores the multifaceted role of serum GGT in CRC, offering insights into its value as a biomarker for risk assessment, prognosis, and therapeutic monitoring, while emphasizing the need for further research to validate its clinical utility.

结直肠癌(CRC)仍然是世界性的重大健康问题,有效的生物标志物对于结直肠癌的早期诊断、预后判断和治疗监测非常必要。血清γ-谷氨酰转移酶(GGT)是谷胱甘肽代谢和细胞应激反应中的一种重要酶,由于其与结直肠癌的潜在联系而备受关注。γ-谷氨酰转移酶是抗氧化系统的重要组成部分,可抵御氧化应激。它主要存在于肝脏、肾脏和胆道等器官中。许多健康问题,如代谢紊乱、肝脏疾病和几种癌症,都与血液中 GGT 水平升高有关。本综述旨在通过研究过去 20 年来的临床研究,阐明血清 GGT 在结直肠癌中的作用。通过对相关文献的全面分析,确定了高血糖转氨酶水平与结肠癌风险、预后和诊断潜力之间的关联。根据流行病学数据,GGT 升高与结肠直肠癌的高风险呈正相关。GGT 对大肠腺瘤的预测能力突出表明,它可用于早期识别和预防方法。其他临床证据表明,CRC 患者的 GGT 水平越高,预后越差,如淋巴结受侵、肿瘤分期晚期和总生存率下降。此外,治疗后 GGT 水平的变化可提供有关患者生存和治疗效果的信息,从而凸显其在治疗监测中的重要性。总之,本综述强调了血清 GGT 在 CRC 中的多方面作用,深入剖析了其作为生物标记物在风险评估、预后判断和治疗监测方面的价值,同时强调了进一步研究验证其临床实用性的必要性。
{"title":"Comprehensing the role of serum GGT in colorectal carcinoma: cancer risk, prognostic and diagnostic significance.","authors":"Sristi Anupam, Simran Goel, Dinesh Kumar Mehta, Rina Das","doi":"10.1007/s12094-024-03791-z","DOIUrl":"https://doi.org/10.1007/s12094-024-03791-z","url":null,"abstract":"<p><p>Effective biomarkers are necessary for early diagnosis, prognosis, and therapy monitoring of colorectal cancer (CRC), a disease that continues to be a major worldwide health problem. Due to a potential connection to colorectal cancer, serum gamma-glutamyl transferase (GGT), an important enzyme in metabolism of glutathione and cellular stress response, has drawn attention. GGT is an essential component of the antioxidant system that protects against oxidative stress. It is mostly found in organs such as the liver, kidneys, and biliary tract. Numerous health problems, such as metabolic disorders, liver illnesses, and several types of cancer, are linked to elevated blood GGT levels. This review aims to clarify the function of serum GGT in colorectal cancer by examining clinical research conducted over the past 20 years. A comprehensive analysis of pertinent literature identifies associations between high blood GGT levels and carcinoma of the colon risk, prognosis, and diagnostic potential. Increased GGT and a higher risk of colorectal cancer are positively correlated, according to epidemiological data consistently. The predictive capacity of GGT for colorectal adenomas underscores its use in early identification and preventive approaches. Additional clinical evidence indicates that higher GGT levels in CRC patients are associated with poorer outcomes, such as invasion of lymph nodes, advanced tumour stages, and decreased overall survival. Furthermore, changes in GGT levels after therapy offer information about patient survival and treatment effectiveness, highlighting its importance in therapy monitoring. In summary, this review underscores the multifaceted role of serum GGT in CRC, offering insights into its value as a biomarker for risk assessment, prognosis, and therapeutic monitoring, while emphasizing the need for further research to validate its clinical utility.</p>","PeriodicalId":50685,"journal":{"name":"Clinical & Translational Oncology","volume":" ","pages":""},"PeriodicalIF":2.8,"publicationDate":"2024-11-20","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142677543","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Development of a prediction model for recurrent parathyroid carcinoma lesions based on 3D-EnCT and ultrasound imaging features. 基于3D-EnCT和超声成像特征的甲状旁腺癌复发病灶预测模型的开发。
IF 2.8 3区 医学 Q2 ONCOLOGY Pub Date : 2024-11-20 DOI: 10.1007/s12094-024-03787-9
Xing Liu, Wenjing Yang, Teng Zhao, Qian Wang, Jiacheng Wang, Dalin Feng, Li Zhao, Hong Shen, Rongfang Shen, Ren Lang, Bojun Wei

Purpose: This study aimed to analyze the three-dimensional enhanced computed tomography (3D-EnCT) and ultrasound imaging features of recurrent parathyroid carcinoma lesions and develop a prediction model based on these features.

Methods: The clinical data of 34 patients (48 cases) with recurrent parathyroid carcinoma who underwent surgical treatment at Beijing Chaoyang Hospital's Thyroid and Neck Surgery Department between January 2017 and April 2024 were retrospectively analyzed. A total of 103 suspicious lesions were identified through a combination of preoperative 3D-EnCT and ultrasound examinations. Patients admitted prior to 1 January 2023 were included in the training set, and those admitted after 1 January 2023 were included in the validation set. In the training set, lesions were categorized as positive or negative based on pathological analysis. Statistically significant imaging features were identified via intergroup comparisons. An imaging prediction model was developed based on the 3D-EnCT and ultrasound features, and the predictive performance of the model was evaluated via receiver operating characteristic curves in the validation set.

Results: Arterial- and venous-phase CT values, lesion boundaries, and blood flow signals were associated with pathological positivity. The 3D-EnCT prediction model based on these features achieved areas under the curve (AUCs) of 0.9 and 0.714 in the training and validation sets, respectively, whereas the ultrasound prediction model achieved AUCs of 0.601 and 0.621, respectively. The 3D-EnCT model demonstrated superior predictive performance.

Conclusion: The 3D-EnCT prediction model demonstrated superior predictive performance for recurrent parathyroid carcinoma lesions.

目的:本研究旨在分析甲状旁腺癌复发病灶的三维增强计算机断层扫描(3D-EnCT)和超声成像特征,并根据这些特征建立预测模型:回顾性分析2017年1月至2024年4月期间在北京朝阳医院甲状腺颈部外科接受手术治疗的34例(48例)复发性甲状旁腺癌患者的临床资料。通过术前3D-EnCT和超声检查,共发现103个可疑病灶。2023年1月1日之前入院的患者被纳入训练集,2023年1月1日之后入院的患者被纳入验证集。在训练集中,病变根据病理分析分为阳性和阴性。通过组间比较确定了具有统计学意义的成像特征。根据 3D-EnCT 和超声特征开发了一个成像预测模型,并通过验证集的接收器操作特征曲线评估了该模型的预测性能:结果:动脉期和静脉期CT值、病变边界和血流信号与病理阳性相关。基于这些特征的 3D-EnCT 预测模型在训练集和验证集的曲线下面积(AUC)分别为 0.9 和 0.714,而超声预测模型的曲线下面积(AUC)分别为 0.601 和 0.621。结论:3D-EnCT 预测模型的预测性能更优越:结论:3D-EnCT预测模型对甲状旁腺癌复发病灶的预测效果更佳。
{"title":"Development of a prediction model for recurrent parathyroid carcinoma lesions based on 3D-EnCT and ultrasound imaging features.","authors":"Xing Liu, Wenjing Yang, Teng Zhao, Qian Wang, Jiacheng Wang, Dalin Feng, Li Zhao, Hong Shen, Rongfang Shen, Ren Lang, Bojun Wei","doi":"10.1007/s12094-024-03787-9","DOIUrl":"https://doi.org/10.1007/s12094-024-03787-9","url":null,"abstract":"<p><strong>Purpose: </strong>This study aimed to analyze the three-dimensional enhanced computed tomography (3D-EnCT) and ultrasound imaging features of recurrent parathyroid carcinoma lesions and develop a prediction model based on these features.</p><p><strong>Methods: </strong>The clinical data of 34 patients (48 cases) with recurrent parathyroid carcinoma who underwent surgical treatment at Beijing Chaoyang Hospital's Thyroid and Neck Surgery Department between January 2017 and April 2024 were retrospectively analyzed. A total of 103 suspicious lesions were identified through a combination of preoperative 3D-EnCT and ultrasound examinations. Patients admitted prior to 1 January 2023 were included in the training set, and those admitted after 1 January 2023 were included in the validation set. In the training set, lesions were categorized as positive or negative based on pathological analysis. Statistically significant imaging features were identified via intergroup comparisons. An imaging prediction model was developed based on the 3D-EnCT and ultrasound features, and the predictive performance of the model was evaluated via receiver operating characteristic curves in the validation set.</p><p><strong>Results: </strong>Arterial- and venous-phase CT values, lesion boundaries, and blood flow signals were associated with pathological positivity. The 3D-EnCT prediction model based on these features achieved areas under the curve (AUCs) of 0.9 and 0.714 in the training and validation sets, respectively, whereas the ultrasound prediction model achieved AUCs of 0.601 and 0.621, respectively. The 3D-EnCT model demonstrated superior predictive performance.</p><p><strong>Conclusion: </strong>The 3D-EnCT prediction model demonstrated superior predictive performance for recurrent parathyroid carcinoma lesions.</p>","PeriodicalId":50685,"journal":{"name":"Clinical & Translational Oncology","volume":" ","pages":""},"PeriodicalIF":2.8,"publicationDate":"2024-11-20","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142677546","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Development of B7-H3 targeted CAR-T cells for renal cell carcinoma therapy: in vitro and in vivo efficacy. 开发用于肾细胞癌治疗的 B7-H3 靶向 CAR-T 细胞:体外和体内疗效。
IF 2.8 3区 医学 Q2 ONCOLOGY Pub Date : 2024-11-19 DOI: 10.1007/s12094-024-03792-y
Wenyi Deng, Lvying Wu, Liuyan Chen, Kuanyin Wang, Na Lin, Lingfeng Zhu, Jin Chen

Purpose: This study aims to develop chimeric antigen receptor (CAR)-T cells specifically targeting B7-H3-expressing renal cell carcinoma (RCC) and to evaluate the feasibility of B7-H3 CAR-T therapy for RCC.

Methods: We analyzed B7-H3 expression in RCC using bioinformatics approaches and confirmed it in tissues and cell lines through immunohistochemical staining and Western blot analysis. A lentiviral vector containing a B7-H3 specific CAR was constructed and transfected into human T cells, with CAR expression verified by flow cytometry. Cytotoxic efficacy was evaluated in co-culture experiments, measuring the production of interferon-gamma (IFN-γ), interleukin-2 (IL-2), granzyme B, and lactate dehydrogenase (LDH) release. Xenograft models in nude mice were used to evaluate tumor growth inhibition by B7-H3 CAR-T cells.

Results: B7-H3 was significantly expressed in RCC and associated with poor prognosis. Elevated levels of B7-H3 expression were validated in both RCC tissues and cell lines. A B7-H3-specific CAR-T cell was developed, achieving a CAR transduction efficiency of 39.85%, as assessed by flow cytometry. In vitro co-culture assays demonstrated that the CAR-T cells exhibited substantial cytotoxic activity against RCC cell lines, with this activity positively correlating with the effector-to-target ratio. Furthermore, the secretion levels of IFN-γ, IL-2, granzyme B, and LDH were significantly increased compared to the control groups. In vivo experiments further confirmed that B7-H3 CAR-T cells significantly inhibited tumor growth.

Conclusion: The current study suggests that B7-H3 CAR-T cells exhibit significant efficacy in targeting and eliminating RCC cells, indicating a promising cellular immunotherapy approach for RCC treatment.

目的:本研究旨在开发特异性靶向B7-H3表达的肾细胞癌(RCC)的嵌合抗原受体(CAR)-T细胞,并评估B7-H3 CAR-T疗法治疗RCC的可行性:我们利用生物信息学方法分析了B7-H3在RCC中的表达,并通过免疫组化染色和Western印迹分析证实了它在组织和细胞系中的表达。我们构建了含有 B7-H3 特异性 CAR 的慢病毒载体,并将其转染到人类 T 细胞中,通过流式细胞术验证 CAR 的表达。在共培养实验中评估了细胞毒性效果,测量了γ干扰素(IFN-γ)、白细胞介素-2(IL-2)、颗粒酶B的产生和乳酸脱氢酶(LDH)的释放。裸鼠异种移植模型用于评估 B7-H3 CAR-T 细胞对肿瘤生长的抑制作用:结果:B7-H3在RCC中明显表达,并与不良预后相关。结果:B7-H3在RCC中明显表达,并与预后不良有关。B7-H3表达水平的升高在RCC组织和细胞系中都得到了验证。经流式细胞术评估,B7-H3特异性CAR-T细胞的CAR转导效率达到39.85%。体外共培养试验表明,CAR-T细胞对RCC细胞系具有很强的细胞毒活性,这种活性与效应细胞与靶细胞的比例呈正相关。此外,与对照组相比,IFN-γ、IL-2、颗粒酶 B 和 LDH 的分泌水平也明显提高。体内实验进一步证实,B7-H3 CAR-T 细胞能明显抑制肿瘤生长:结论:本研究表明,B7-H3 CAR-T细胞在靶向和清除RCC细胞方面表现出明显的疗效,这表明细胞免疫疗法在RCC治疗中大有可为。
{"title":"Development of B7-H3 targeted CAR-T cells for renal cell carcinoma therapy: in vitro and in vivo efficacy.","authors":"Wenyi Deng, Lvying Wu, Liuyan Chen, Kuanyin Wang, Na Lin, Lingfeng Zhu, Jin Chen","doi":"10.1007/s12094-024-03792-y","DOIUrl":"10.1007/s12094-024-03792-y","url":null,"abstract":"<p><strong>Purpose: </strong>This study aims to develop chimeric antigen receptor (CAR)-T cells specifically targeting B7-H3-expressing renal cell carcinoma (RCC) and to evaluate the feasibility of B7-H3 CAR-T therapy for RCC.</p><p><strong>Methods: </strong>We analyzed B7-H3 expression in RCC using bioinformatics approaches and confirmed it in tissues and cell lines through immunohistochemical staining and Western blot analysis. A lentiviral vector containing a B7-H3 specific CAR was constructed and transfected into human T cells, with CAR expression verified by flow cytometry. Cytotoxic efficacy was evaluated in co-culture experiments, measuring the production of interferon-gamma (IFN-γ), interleukin-2 (IL-2), granzyme B, and lactate dehydrogenase (LDH) release. Xenograft models in nude mice were used to evaluate tumor growth inhibition by B7-H3 CAR-T cells.</p><p><strong>Results: </strong>B7-H3 was significantly expressed in RCC and associated with poor prognosis. Elevated levels of B7-H3 expression were validated in both RCC tissues and cell lines. A B7-H3-specific CAR-T cell was developed, achieving a CAR transduction efficiency of 39.85%, as assessed by flow cytometry. In vitro co-culture assays demonstrated that the CAR-T cells exhibited substantial cytotoxic activity against RCC cell lines, with this activity positively correlating with the effector-to-target ratio. Furthermore, the secretion levels of IFN-γ, IL-2, granzyme B, and LDH were significantly increased compared to the control groups. In vivo experiments further confirmed that B7-H3 CAR-T cells significantly inhibited tumor growth.</p><p><strong>Conclusion: </strong>The current study suggests that B7-H3 CAR-T cells exhibit significant efficacy in targeting and eliminating RCC cells, indicating a promising cellular immunotherapy approach for RCC treatment.</p>","PeriodicalId":50685,"journal":{"name":"Clinical & Translational Oncology","volume":" ","pages":""},"PeriodicalIF":2.8,"publicationDate":"2024-11-19","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142669804","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Correction: Prediction model for major bleeding in anticoagulated patients with cancer-associated venous thromboembolism using machine learning and natural language processing. 更正:利用机器学习和自然语言处理技术建立癌症相关静脉血栓栓塞抗凝患者大出血预测模型。
IF 2.8 3区 医学 Q2 ONCOLOGY Pub Date : 2024-11-19 DOI: 10.1007/s12094-024-03780-2
Andrés J Muñoz Martín, Ramón Lecumberri, Juan Carlos Souto, Berta Obispo, Antonio Sanchez, Jorge Aparicio, Cristina Aguayo, David Gutierrez, Andrés García Palomo, Diego Benavent, Miren Taberna, María Carmen Viñuela-Benéitez, Daniel Arumi, Miguel Ángel Hernández-Presa
{"title":"Correction: Prediction model for major bleeding in anticoagulated patients with cancer-associated venous thromboembolism using machine learning and natural language processing.","authors":"Andrés J Muñoz Martín, Ramón Lecumberri, Juan Carlos Souto, Berta Obispo, Antonio Sanchez, Jorge Aparicio, Cristina Aguayo, David Gutierrez, Andrés García Palomo, Diego Benavent, Miren Taberna, María Carmen Viñuela-Benéitez, Daniel Arumi, Miguel Ángel Hernández-Presa","doi":"10.1007/s12094-024-03780-2","DOIUrl":"10.1007/s12094-024-03780-2","url":null,"abstract":"","PeriodicalId":50685,"journal":{"name":"Clinical & Translational Oncology","volume":" ","pages":""},"PeriodicalIF":2.8,"publicationDate":"2024-11-19","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142669799","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Analysis of therapeutic effects and influencing factors of ICIs in lung-cancer patients. 分析 ICIs 对肺癌患者的治疗效果和影响因素。
IF 2.8 3区 医学 Q2 ONCOLOGY Pub Date : 2024-11-19 DOI: 10.1007/s12094-024-03767-z
Jun Luo, Li Li, HongGui Wang, Xian Zhang, FangTing He, Meng Shi, Xin Zhang, Rui Tang, Yong Bao
<p><strong>Objective: </strong>The aim of this retrospective study was to analyze the efficacy and risk factors of immune checkpoint inhibitors (ICIs) in lung cancer patients.</p><p><strong>Methods: </strong>One hundred lung cancer patients who were treated in our hospital from May 2021 to May 2023 were selected as the study subjects and divided into chemotherapy group (n = 50) and ICIs group (n = 50), in which the chemotherapy group was given the combined treatment of vincristine and cisplatin (NP), while the ICIs group was given ICIs for treatment. The therapeutic effect and adverse reactions (hypertriglyceridemia, anemia, hypertension and hypoproteinemia) of the two groups were compared, and fasting venous blood was collected. The levels of carcinoembryonic antigen (CEA) and cancer antigen 199 (CA199) were compared between the two groups before and after treatment. According to the therapeutic effect, 100 patients with lung cancer were divided into complete remission (CR) + partial remission (PR) group (n = 52) and stable (SD) + progressive (PD) group (n = 48). The clinical data and pathologic data of the two groups were compared.</p><p><strong>Results: </strong>The rates of objective effective rate (ORR) in chemotherapy group and ICIs group were 36.00% and 68.00% respectively, and the level of ORR in ICIs group was significantly higher than that in chemotherapy group, with statistical significance (P < 0.05). There was no significant difference in serum CEA and CA199 levels between the two groups before operation (P > 0.05). Three months after operation, the serum CEA and CA199 levels in ICIs group were significantly lower than those in chemotherapy group, and the difference was statistically significant (P < 0.05). The adverse reactions of hypertriglyceridemia, anemia, hypertension and hypoproteinemia in chemotherapy group and ICIs group during treatment were all grade 1-2, and the incidence of adverse reactions was similar between the two groups (P > 0.05). There was no significant difference in sex, age, anatomic position, pathologic type, smoking history and differentiation between the two groups (P > 0.05). In SD + PD group, the preoperative maximum tumor diameter > 4 cm, tumor node metastasis (TNM) stage IV, lactate dehydrogenase (LDH) ≥ 183 U/L, and tumor volume ≥ 120m<sup>3</sup> were significantly higher than those in CR + PR group, and the prognostic nutritional index (PNI) ≥ 41.8 and the proportion of ICIs were significantly lower than those in CR + PR group, with statistical significance (P < 0.05). Multifactorial logistic regression analysis showed that preoperative maximum tumor diameter > 4 cm and LDH ≥ 183 U/L were risk factors for poor lung cancer outcome, and PNI ≥ 41.8 and ICIs treatment were protective factors for poor lung cancer outcome (P < 0.05).</p><p><strong>Conclusion: </strong>ICIs is effective in the treatment of lung cancer, which can obviously reduce the tumor load and has high safety. In addition, the maximum t
研究目的本回顾性研究旨在分析免疫检查点抑制剂(ICIs)在肺癌患者中的疗效和风险因素:选取2021年5月至2023年5月在我院接受治疗的100例肺癌患者作为研究对象,分为化疗组(n=50)和ICIs组(n=50),其中化疗组给予长春新碱和顺铂(NP)联合治疗,ICIs组给予ICIs治疗。比较两组的疗效和不良反应(高甘油三酯血症、贫血、高血压和低蛋白血症),并采集空腹静脉血。比较两组患者治疗前后癌胚抗原(CEA)和癌抗原 199(CA199)的水平。根据疗效将 100 例肺癌患者分为完全缓解(CR)+部分缓解(PR)组(52 例)和稳定(SD)+进展(PD)组(48 例)。比较两组的临床数据和病理数据:化疗组和 ICIs 组的客观有效率(ORR)分别为 36.00% 和 68.00%,ICIs 组的 ORR 水平明显高于化疗组,差异有统计学意义(P 0.05)。术后三个月,ICIs 组血清 CEA 和 CA199 水平明显低于化疗组,差异有统计学意义(P 0.05)。两组患者在性别、年龄、解剖位置、病理类型、吸烟史和分化程度等方面无明显差异(P>0.05)。SD+PD组术前肿瘤最大直径>4 cm、肿瘤结节转移(TNM)分期Ⅳ期、乳酸脱氢酶(LDH)≥183 U/L、肿瘤体积≥120 m3明显高于CR+PR组,预后营养指数(PNI)≥41.8 和 ICIs 比例明显低于 CR + PR 组,差异有统计学意义(P 4 cm 和 LDH≥ 183 U/L是肺癌不良预后的危险因素,PNI≥41.8 和 ICIs 治疗是肺癌不良预后的保护因素(P 结论:ICIs 是治疗肺癌的有效方法:ICIs 治疗肺癌效果显著,能明显减轻肿瘤负荷,安全性高。此外,肿瘤最大直径和 LDH 是影响肺癌不良预后的危险因素。高 PNI 水平和 ICIs 治疗有助于提高肺癌的疗效,早期监测有助于指导治疗方案和评估疗效。
{"title":"Analysis of therapeutic effects and influencing factors of ICIs in lung-cancer patients.","authors":"Jun Luo, Li Li, HongGui Wang, Xian Zhang, FangTing He, Meng Shi, Xin Zhang, Rui Tang, Yong Bao","doi":"10.1007/s12094-024-03767-z","DOIUrl":"10.1007/s12094-024-03767-z","url":null,"abstract":"&lt;p&gt;&lt;strong&gt;Objective: &lt;/strong&gt;The aim of this retrospective study was to analyze the efficacy and risk factors of immune checkpoint inhibitors (ICIs) in lung cancer patients.&lt;/p&gt;&lt;p&gt;&lt;strong&gt;Methods: &lt;/strong&gt;One hundred lung cancer patients who were treated in our hospital from May 2021 to May 2023 were selected as the study subjects and divided into chemotherapy group (n = 50) and ICIs group (n = 50), in which the chemotherapy group was given the combined treatment of vincristine and cisplatin (NP), while the ICIs group was given ICIs for treatment. The therapeutic effect and adverse reactions (hypertriglyceridemia, anemia, hypertension and hypoproteinemia) of the two groups were compared, and fasting venous blood was collected. The levels of carcinoembryonic antigen (CEA) and cancer antigen 199 (CA199) were compared between the two groups before and after treatment. According to the therapeutic effect, 100 patients with lung cancer were divided into complete remission (CR) + partial remission (PR) group (n = 52) and stable (SD) + progressive (PD) group (n = 48). The clinical data and pathologic data of the two groups were compared.&lt;/p&gt;&lt;p&gt;&lt;strong&gt;Results: &lt;/strong&gt;The rates of objective effective rate (ORR) in chemotherapy group and ICIs group were 36.00% and 68.00% respectively, and the level of ORR in ICIs group was significantly higher than that in chemotherapy group, with statistical significance (P &lt; 0.05). There was no significant difference in serum CEA and CA199 levels between the two groups before operation (P &gt; 0.05). Three months after operation, the serum CEA and CA199 levels in ICIs group were significantly lower than those in chemotherapy group, and the difference was statistically significant (P &lt; 0.05). The adverse reactions of hypertriglyceridemia, anemia, hypertension and hypoproteinemia in chemotherapy group and ICIs group during treatment were all grade 1-2, and the incidence of adverse reactions was similar between the two groups (P &gt; 0.05). There was no significant difference in sex, age, anatomic position, pathologic type, smoking history and differentiation between the two groups (P &gt; 0.05). In SD + PD group, the preoperative maximum tumor diameter &gt; 4 cm, tumor node metastasis (TNM) stage IV, lactate dehydrogenase (LDH) ≥ 183 U/L, and tumor volume ≥ 120m&lt;sup&gt;3&lt;/sup&gt; were significantly higher than those in CR + PR group, and the prognostic nutritional index (PNI) ≥ 41.8 and the proportion of ICIs were significantly lower than those in CR + PR group, with statistical significance (P &lt; 0.05). Multifactorial logistic regression analysis showed that preoperative maximum tumor diameter &gt; 4 cm and LDH ≥ 183 U/L were risk factors for poor lung cancer outcome, and PNI ≥ 41.8 and ICIs treatment were protective factors for poor lung cancer outcome (P &lt; 0.05).&lt;/p&gt;&lt;p&gt;&lt;strong&gt;Conclusion: &lt;/strong&gt;ICIs is effective in the treatment of lung cancer, which can obviously reduce the tumor load and has high safety. In addition, the maximum t","PeriodicalId":50685,"journal":{"name":"Clinical & Translational Oncology","volume":" ","pages":""},"PeriodicalIF":2.8,"publicationDate":"2024-11-19","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142669792","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Correction: Impact of a comprehensive geriatric assessment to manage elderly patients with locally advanced non-small-cell lung cancers: a multicenter prospective study. 更正:一项多中心前瞻性研究:综合老年病学评估对管理局部晚期非小细胞肺癌老年患者的影响。
IF 2.8 3区 医学 Q2 ONCOLOGY Pub Date : 2024-11-16 DOI: 10.1007/s12094-024-03766-0
Maria Arnal Rondan, Alfredo Sánchez-Hernández, David Lorente Estellés, Jóse García Sánchez, Francisco de Asís Aparisi Aparisi, Jorge Soler López, Raquel Ten Benajes, Regina Gironés Sarrió
{"title":"Correction: Impact of a comprehensive geriatric assessment to manage elderly patients with locally advanced non-small-cell lung cancers: a multicenter prospective study.","authors":"Maria Arnal Rondan, Alfredo Sánchez-Hernández, David Lorente Estellés, Jóse García Sánchez, Francisco de Asís Aparisi Aparisi, Jorge Soler López, Raquel Ten Benajes, Regina Gironés Sarrió","doi":"10.1007/s12094-024-03766-0","DOIUrl":"https://doi.org/10.1007/s12094-024-03766-0","url":null,"abstract":"","PeriodicalId":50685,"journal":{"name":"Clinical & Translational Oncology","volume":" ","pages":""},"PeriodicalIF":2.8,"publicationDate":"2024-11-16","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142644950","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
期刊
Clinical & Translational Oncology
全部 Acc. Chem. Res. ACS Applied Bio Materials ACS Appl. Electron. Mater. ACS Appl. Energy Mater. ACS Appl. Mater. Interfaces ACS Appl. Nano Mater. ACS Appl. Polym. Mater. ACS BIOMATER-SCI ENG ACS Catal. ACS Cent. Sci. ACS Chem. Biol. ACS Chemical Health & Safety ACS Chem. Neurosci. ACS Comb. Sci. ACS Earth Space Chem. ACS Energy Lett. ACS Infect. Dis. ACS Macro Lett. ACS Mater. Lett. ACS Med. Chem. Lett. ACS Nano ACS Omega ACS Photonics ACS Sens. ACS Sustainable Chem. Eng. ACS Synth. Biol. Anal. Chem. BIOCHEMISTRY-US Bioconjugate Chem. BIOMACROMOLECULES Chem. Res. Toxicol. Chem. Rev. Chem. Mater. CRYST GROWTH DES ENERG FUEL Environ. Sci. Technol. Environ. Sci. Technol. Lett. Eur. J. Inorg. Chem. IND ENG CHEM RES Inorg. Chem. J. Agric. Food. Chem. J. Chem. Eng. Data J. Chem. Educ. J. Chem. Inf. Model. J. Chem. Theory Comput. J. Med. Chem. J. Nat. Prod. J PROTEOME RES J. Am. Chem. Soc. LANGMUIR MACROMOLECULES Mol. Pharmaceutics Nano Lett. Org. Lett. ORG PROCESS RES DEV ORGANOMETALLICS J. Org. Chem. J. Phys. Chem. J. Phys. Chem. A J. Phys. Chem. B J. Phys. Chem. C J. Phys. Chem. Lett. Analyst Anal. Methods Biomater. Sci. Catal. Sci. Technol. Chem. Commun. Chem. Soc. Rev. CHEM EDUC RES PRACT CRYSTENGCOMM Dalton Trans. Energy Environ. Sci. ENVIRON SCI-NANO ENVIRON SCI-PROC IMP ENVIRON SCI-WAT RES Faraday Discuss. Food Funct. Green Chem. Inorg. Chem. Front. Integr. Biol. J. Anal. At. Spectrom. J. Mater. Chem. A J. Mater. Chem. B J. Mater. Chem. C Lab Chip Mater. Chem. Front. Mater. Horiz. MEDCHEMCOMM Metallomics Mol. Biosyst. Mol. Syst. Des. Eng. Nanoscale Nanoscale Horiz. Nat. Prod. Rep. New J. Chem. Org. Biomol. Chem. Org. Chem. Front. PHOTOCH PHOTOBIO SCI PCCP Polym. Chem.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
0
微信
客服QQ
Book学术公众号 扫码关注我们
反馈
×
意见反馈
请填写您的意见或建议
请填写您的手机或邮箱
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
现在去查看 取消
×
提示
确定
Book学术官方微信
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术
文献互助 智能选刊 最新文献 互助须知 联系我们:info@booksci.cn
Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。
Copyright © 2023 Book学术 All rights reserved.
ghs 京公网安备 11010802042870号 京ICP备2023020795号-1